Search research articles
Contact Us
Filters
Showing results (211-220 of 333) with videos related to
Page
of 34
Sort By:
Pediatrics
|
October 21, 2009
Clinical and economic effects of iNO in premature newborns with respiratory failure at 1 year
R Scott Watson, Gilles Clermont, John P Kinsella, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
January 28, 2026
Breaking the PROMISE: poor association between brain volume loss and clinical disability worsening over 2 years of follow-up in primary progressive multiple sclerosis
Marcus Koch, Jop Mostert, Eva M Strijbis, et al.
Genetic Epidemiology
|
October 21, 2021
Mendelian randomization in the multivariate general linear model framework
Phillip H Allman, Inmaculada Aban, Dustin M Long, et al.
Frontiers in Rehabilitation Sciences
|
October 3, 2022
Effects of exercise on sleep spindles in Parkinson's disease
Adeel Ali Memon, Corina Catiul, Zachary Irwin, et al.
Plos One
|
February 23, 2011
Chronic cerebrospinal vascular insufficiency is not associated with HLA DRB1*1501 status in multiple sclerosis patients
Bianca Weinstock-Guttman, Robert Zivadinov, Gary Cutter, et al.
Academic Radiology
|
September 14, 2024
Improving the Assessment of Axonal Injury in Early Multiple Sclerosis
Ahmad A Toubasi, Gary Cutter, Caroline Gheen, et al.
Journal of Magnetic Resonance Imaging : JMRI
|
December 10, 2024
Improving the Detection of Myelin Integrity in Multiple Sclerosis Using Selective Inversion Recovery for MRI With Quantitative Magnetization Transfer
Ahmad A Toubasi, Dhairya A Lakhani, Gary Cutter, et al.
BMJ Open
|
December 4, 2012
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study
Douglas S Goodin, George C Ebers, Gary Cutter, et al.
Archives of Neurology
|
September 10, 2008
Reproducibility of optical coherence tomography in multiple sclerosis
Deanna Cettomai, Mathew Pulicken, Eliza Gordon-Lipkin, et al.
Lancet (London, England)
|
February 11, 2014
EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial
Andrew S C Rice, Robert H Dworkin, Tom D McCarthy, et al.
Page
of 34
Search research articles
Search
Showing results (211-220 of 333) with videos related to
Sort By:
Page
of 34
Pediatrics
|
October 21, 2009
Clinical and economic effects of iNO in premature newborns with respiratory failure at 1 year
R Scott Watson, Gilles Clermont, John P Kinsella, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
January 28, 2026
Breaking the PROMISE: poor association between brain volume loss and clinical disability worsening over 2 years of follow-up in primary progressive multiple sclerosis
Marcus Koch, Jop Mostert, Eva M Strijbis, et al.
Genetic Epidemiology
|
October 21, 2021
Mendelian randomization in the multivariate general linear model framework
Phillip H Allman, Inmaculada Aban, Dustin M Long, et al.
Frontiers in Rehabilitation Sciences
|
October 3, 2022
Effects of exercise on sleep spindles in Parkinson's disease
Adeel Ali Memon, Corina Catiul, Zachary Irwin, et al.
Plos One
|
February 23, 2011
Chronic cerebrospinal vascular insufficiency is not associated with HLA DRB1*1501 status in multiple sclerosis patients
Bianca Weinstock-Guttman, Robert Zivadinov, Gary Cutter, et al.
Academic Radiology
|
September 14, 2024
Improving the Assessment of Axonal Injury in Early Multiple Sclerosis
Ahmad A Toubasi, Gary Cutter, Caroline Gheen, et al.
Journal of Magnetic Resonance Imaging : JMRI
|
December 10, 2024
Improving the Detection of Myelin Integrity in Multiple Sclerosis Using Selective Inversion Recovery for MRI With Quantitative Magnetization Transfer
Ahmad A Toubasi, Dhairya A Lakhani, Gary Cutter, et al.
BMJ Open
|
December 4, 2012
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study
Douglas S Goodin, George C Ebers, Gary Cutter, et al.
Archives of Neurology
|
September 10, 2008
Reproducibility of optical coherence tomography in multiple sclerosis
Deanna Cettomai, Mathew Pulicken, Eliza Gordon-Lipkin, et al.
Lancet (London, England)
|
February 11, 2014
EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial
Andrew S C Rice, Robert H Dworkin, Tom D McCarthy, et al.
Page
of 34